Date published: 2026-4-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Fluconazole N-Oxide (CAS 1997296-62-4)

0.0(0)
Write a reviewAsk a question

Alternate Names:
Fluconazole mono-N-Oxide
CAS Number:
1997296-62-4
Molecular Weight:
322.27
Molecular Formula:
C13H12F2N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Fluconazole N-Oxide is an interesting derivative of fluconazole, primarily utilized for its unique properties in the realm of biochemical and agricultural research. This compound exhibits a distinct mechanism of action, where its oxidative modification—namely, the N-oxide formation—plays a pivotal role. By altering its interaction with fungal enzymes, Fluconazole N-Oxide provides a novel pathway for studying the resistance mechanisms of various fungal species. Its utility extends to facilitating the exploration of enzyme inhibition and metabolic pathways in fungi, offering insights into fungal biology and potential control strategies. Researchers often leverage this compound to dissect the molecular underpinnings of fungal growth and proliferation, making it useful in the development of antifungal strategies and the study of fungal pathogenesis in agricultural settings. The oxidative modification imbues Fluconazole N-Oxide with distinctive properties that enhance its application in experimental models, thereby broadening our understanding of fungal ecology and resistance mechanisms.


Fluconazole N-Oxide (CAS 1997296-62-4) References

  1. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants.  |  Uko, S., et al. 2006. Pediatrics. 117: 1243-52. PMID: 16585321
  2. The disposition and metabolism of [14C]fluconazole in humans.  |  Brammer, KW., et al. 1991. Drug Metab Dispos. 19: 764-7. PMID: 1680653
  3. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.  |  Gubbins, PO. 2011. Expert Opin Drug Metab Toxicol. 7: 1411-29. PMID: 21995615
  4. Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.  |  Charoo, N., et al. 2014. J Pharm Sci. 103: 3843-3858. PMID: 25312492
  5. Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.  |  Laverdiere, M., et al. 2014. Can J Infect Dis Med Microbiol. 25: 327-43. PMID: 25587296
  6. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.  |  Charoo, NA., et al. 2015. J Pharm Pharmacol. 67: 1156-69. PMID: 25828546
  7. Electrochemistry-mass spectrometry for in-vitro determination of selected chemotherapeutics and their electrochemical products in comparison to in-vivo approach.  |  Szultka-Mlynska, M. and Buszewski, B. 2016. Talanta. 160: 694-703. PMID: 27591665
  8. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.  |  Amsden, JR. and Gubbins, PO. 2017. Expert Opin Drug Metab Toxicol. 13: 1135-1146. PMID: 29022838
  9. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.  |  Sanglard, D., et al. 1996. Antimicrob Agents Chemother. 40: 2300-5. PMID: 8891134

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Fluconazole N-Oxide, 1 mg

sc-498151
1 mg
$380.00